![Stef Heylen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stef Heylen is currently a Director at Exevir Bio BV since 2020.
Previously, he worked as a Managing Director at Janssen Pharmaceutica NV.
He holds a doctorate degree from Katholieke Universiteit Leuven.
| Companies | Position | Start |
|---|---|---|
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Develops antibody-based therapies | Director/Board Member | 02/11/2020 |
| Companies | Position | End |
|---|---|---|
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Engages in research, development and production of drugs | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 3 |
|---|---|
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Pharmaceutica NV
Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Engages in research, development and production of drugs | Health Technology |
Exevir Bio BV
Exevir Bio BV Pharmaceuticals: MajorHealth Technology Develops antibody-based therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
